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Optimisation of the dibromomaleimide (DBM)
platform for native antibody conjugation by
accelerated post-conjugation hydrolysis†
Maurício Morais, João P. M. Nunes, Kersti Karu, Nafsika Forte, Irene Benni,
Mark E. B. Smith, Stephen Caddick, Vijay Chudasama* and James R. Baker*
Disulﬁde bridging oﬀers a convenient approach to generate site-selective antibody conjugates from
native antibodies. To optimise the reagents available to achieve this strategy, we describe here the use of
dibromomaleimides designed to undergo accelerated post-conjugation hydrolysis. Conjugation and
hydrolysis, which serve to ‘lock’ the conjugates as robustly stable maleamic acids, is achieved in just over
1 h. This dramatic acceleration is also shown to infer signiﬁcant improvements in homogeneity, as
demonstrated by mass spectrometry analysis.
Introduction
Antibody bioconjugation is a key technological challenge in
chemical biology, enabling a broad range of applications from
targeted therapeutics (e.g. antibody–drug conjugates; ADCs) to
radioimmunoconjugates and immunoassays.1 Conjugation to
antibodies is most readily achieved by exploiting the reactivity
of lysine and cysteine residues to specific electrophilic
reagents. There are >80 lysine residues in a typical antibody,
and it has been estimated for ADCs that an average loading of
3–4 drugs per antibody leads to around 106 molecular species
present in the resulting heterogeneous conjugates.2 The use of
such complex mixtures in therapeutics is far from optimal,
as each component will have a diﬀerent pharmacological
profile.2b,3 An alternative strategy is to release cysteine residues
as sites for attachment by reduction of the interchain disulfide
bonds, of which there are four in the major therapeutically
relevant isotype (IgG1). Loading each of the cysteines with a
reactive reagent, most commonly achieved using classical
maleimides, still aﬀords a heterogeneous mixture of products
with drug-to-antibody ratios (DARs) of 0, 2, 4, 6 and 8 as the
major components.4 The higher loaded species present have
been identified as having reduced stability,5 and poorer out-
comes in vivo due to their accelerated clearance.4,6
There is significant evidence that increased homogeneity in
conjugates will aﬀord improved therapeutic windows,2b,6,7 and
thus approaches for site-selective conjugation are gaining
momentum and can be expected to form a key component of
future generations of ADCs.8 These include the use of genetic
engineering to incorporate cysteine mutants, non-natural
amino-acids or enzymatic recognition sequences as handles
for controlled drug loading.7a,8,9 Site-selective methods which
avoid this requirement for engineering can oﬀer the further
advantage of being directly applicable to native antibodies. To
this end disulfide bridging is a highly promising strategy, in
which the interchain disulfide bonds are targeted with
reagents which reconnect the two cysteine residues.8b,10 This
approach aims to generate antibody conjugates with a con-
trolled loading of one drug per disulfide bond, and thus a
DAR of 4 in IgG1s.
We have recently described the use of a class of modified
maleimide reagents, known as next generation maleimides
(NGMs),11 which are able to achieve eﬃcient disulfide bridging
and thus represent a platform for site-selective ADC develop-
ment (Fig. 1).12 We have shown that dithiophenolmaleimide–
monomethyl auristatin E (DTPM–MMAE) reagents can aﬀord
ADCs which oﬀer potent and selective tumor cell killing
activity in vitro12d and in vivo.13 In addition to aﬀording access
to a narrow range of DAR species, with an average close to
Fig. 1 NGM–ADC conjugates constructed by disulﬁde bridging.12d
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four, the NGMs provide a route to serum stable conjugates.
This is achieved by hydrolysis of the maleimide ring to ‘lock’
the products as maleamic acids (see the structure shown in
Fig. 1).12d
Jackson et al. have also applied alternative NGMs, dibromo-
maleimides (DBMs), to generate analogous ADCs using MMAF
as the payload, and have confirmed that the resultant ADCs
oﬀer improved in vivo eﬃcacy compared to classical maleimide
conjugates.14 Notably no hydrolysis step is included in this
DBM–MMAF conjugation, and the resultant conjugates can be
expected to cleave over several days in serum due to thiol
exchange reactions.12d
These approaches to NGM–ADCs, whilst highly promising,
require optimisation. Post-conjugation hydrolysis is key to
ensure robust serum stability, to prevent the loss of free drug
leading to oﬀ-site toxicity; however the current prolonged con-
ditions described, 72 h at pH 8.4,12d are sub-optimal. This will
serve to increase process times for downstream product develop-
ment and can even introduce undesirable heterogeneity as
shown herein. In this work we describe an investigation into
accelerated hydrolysis, by means of linker design and conju-
gation conditions, and show that a dramatic increase in the rate
of the reaction sequence is facilitated along with improved
homogeneity. Whilst this optimisation is carried out in the
context of ADCs, it also has implications on the design of NGM
reagents for bioconjugation more widely, as these reagents are
finding increasing application on diverse scaﬀolds ranging
from peptides and proteins to polymers and surfaces.15
Results and discussion
Dibromomaleimide (DBM) reagent selection and synthesis
We chose to employ DBMs, which represent the simplest and
most accessible disulfide bridging reagents, with varying linkers
attached to the maleimide nitrogen. By varying from the C-6
(caproyl) linker which has been used in previous work to a C-2
(glycine derived) or an aryl linker, we expected to eﬀect an
increase in the rate of hydrolysis (due to increased electron
withdrawal from the imide).16 Previous work has shown that
aryl linkers on classical maleimides and DTPMs aﬀord antibody
conjugates which undergo accelerated hydrolysis.12c,17
The synthesis of DBM reagents is commonly achieved by
treatment of dibromomaleic anhydride (or commercially avail-
able diacid18) with an amine, refluxing in acetic acid to induce
ring closure. Alternatively, an N-methoxy carbonyl activated
DBM can be employed when a milder, room temperature,
approach is required.19 Here we favoured a diﬀerent strategy,
in which the linker was pre-installed with the DBM, and an
appended carboxylic acid could then be coupled with an
amine. Notably the use of an NHS ester (comparable to ubiqui-
tously employed heterobifunctional maleimide reagents) led to
competing attack on the DBM to generate aminomaleimides.
This highlights the increased electrophilicity of these substi-
tuted maleimides. To overcome this, a more active acylating
agent is required, which can be achieved by the use of an
EEDQ coupling (Scheme 1). Using readily synthesised acids
1–3 (see the ESI†) this strategy gave access to three model
reagents 4–6, incorporating an alkyne handle suitable for sub-
sequent functionalisation if desired.
LC-MS validation and propensity of IgG1 to form disulfide
isomers
We chose clinically relevant IgG1 trastuzumab20 as a model
antibody for our conjugation study, and sought to evaluate the
LC-MS method that would be crucial to assessing the hom-
ogeneity of the conjugates. Trastuzumab was thus deglycosy-
lated using PNGase F, and analysed by capillary electrospray
ionisation on a Q-TOF LC-MS. The result was a single main
species, corresponding to the deglycosylated full antibody
(Fig. 2A, see the ESI† for raw data). Upon reduction with TCEP
free heavy and light chains are observed (Fig. 2B), due to the
denaturing conditions of the LC-MS. Finally we reoxidised this
sample, using Ellman’s reagent, to represent a control for the
data that could be expected upon reformation of the covalent
attachments between the chains (Fig. 2C). Intriguingly, whilst
reoxidation was highly eﬃcient, the product was formed as
Fig. 2 Deconvoluted LC-MS data on: A – trastuzumab (mass observed
145 167, expected 145 167); B – reduced trastuzumab (mass observed
23 440 and 49 150, expected 23 440 and 49 150); C – reoxidised trastu-
zumab using Ellman’s reagent (observed 72 585 and 145 167, expected
72 584 and 145 167).
Scheme 1 Synthesis of dibromomaleimide reagents 4–6 with C-6, C-2
and aryl linkers.
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two isomers; the full antibody (minor) and the ‘half-antibody’
(major). This half-antibody is simply the product in which the
disulfides in the hinge region of the antibody have reformed
in an intrachain, rather than interchain fashion, and is thus
observed by the denaturing LC-MS method. This competitive
inter- and intramolecular reactivity matches the outcome of
disulfide bridging reagents12c,14 and suggests that IgG1s are sus-
ceptible to such disulfide scrambling. It should be noted that
oxidation under other conditions, such as dehydroascorbic
acid,21 is known to generate the native disulfide configuration.
We postulate that the diﬀerence is due to Ellman’s reagent’s
high reactivity, trapping the intrachain connectivity as a kinetic
outcome. Indeed treatment of the isomeric mixture with an
alkyl thiol (cysteamine, 10 equiv.) re-equilibrates the system to
generate the native connectivity (ESI Fig. S8†).
Conjugation of DBM-linker reagents 4–6 with optimisation
This initial MS data served as a benchmark for our conjugation
experiments. Thus trastuzumab was reduced with TCEP and
treated with DBM reagent 4, which contains the C-6 linker and
is expected to hydrolyse slowly post-conjugation. The LC-MS
analysis (Fig. 3A) revealed that the conjugate was a mixture of
species – the major components being the half antibody (with
two attached NGM linkers), and non-crosslinked light and
heavy chains. A closer inspection of the light chain mass
reveals that the major species (23 361 Da) has undergone a
decarboxylative cleavage of the C-terminal cysteine. This reac-
tion, which has previously been observed to occur on trastuzu-
mab–thiomaleimide conjugates under photochemical con-
ditions,22 occurs even if light is excluded.
To preclude this undesirable heterogeneity, we proposed
that rapid hydrolysis post-conjugation would be beneficial as it
would remove the reactive dithiomaleimide functional group
from the conjugate. Indeed the use of the C-2 and aryl linker (4
and 5) avoided this competing decarboxylative side-reaction,
generating much improved homogeneity (ESI Fig. S11 and S13†).
An additional improvement was achieved by switching the pH
from 8.0 to 8.5, to further accelerate hydrolysis (Fig. 3B and C).
For both linkers the LC-MS data confirm that two isomeric
products are formed almost exclusively, with one containing
inter-heavy chain bridges and the other intrachain bridges;
both represent antibody conjugates loaded with 4 DBMs. The
raw data (see the ESI†) also give further insights, confirming
this major improvement in homogeneity and showing that the
half-antibody conjugate envelope (1400–2200 m/z) and the full
antibody conjugate envelope (2600–3400 m/z) approach a 1 : 1
ratio in the optimised conjugates. SDS-PAGE analysis (ESI
Fig. S2 and S3†) further confirms this improvement in homo-
geneity, and indicates that the full antibody conjugate now
represents the major species. Overall these data reveal that
these accelerated hydrolysis DBM reagents oﬀer eﬃcient and
highly homogeneous conjugation with a loading of 4. Notably
the LC-MS profile is similar to that obtained from the Ellman’s
reoxidation (Fig. 1C), indicating that the DBM bridging oﬀers
a comparably eﬃcient mode of reactivity to disulfide
reformation.
Rate of hydrolysis post-conjugation
To investigate the rate of hydrolysis of these conjugates we
exploited the convenient absorbance of the dithiomaleimides at
∼400 nm 23 which is lost upon conversion to the corresponding
maleamic acid (see the ESI†). The kinetic data at pH 8.5 confirm
the dramatic acceleration inferred by the C-2 and aryl linkers
(Fig. 4); the hydrolysis half-lives of 16–19 min (cf. 48 h for C-6
linker) are comparable to classical maleimides containing aryl
linkers.17 These data confirmed that the conjugates using C-2
and aryl linkers are almost completely hydrolysed in an hour.
Rapid hydrolysis of DBM reagents
Given the acceleration in hydrolysis aﬀorded the dithiomale-
imide bridges by the electron withdrawing linkers, we were
intrigued to compare the hydrolytic lability of the dibromo-
maleimide reagents themselves. Using a similar approach, we
monitored the disappearance of absorbance associated with
dibromomaleimide; in this case at 325 nm. The C-2 and C-6
linkers (reagents 4 and 5) were selected for the study, as they
oﬀered clearly distinguishable absorbances at this wavelength,
which are again lost upon hydrolysis to generate the maleamic
acids (see the ESI†). Intriguingly the dibromomaleimides were
Fig. 3 Deconvoluted LC-MS data on the trastuzumab–NGM conjugates:
A – using DBM-C6-alkyne 4 at pH 8.0 (mass observed 73 119* and 73322,
expected 73 117); B – using DBM-C2-alkyne 5 at pH 8.5 (mass observed
73001 and 145 991, expected 73005 and 146008); C – using DBM-aryl-
alkyne 6 at pH 8.5 (mass observed 73 125 and 146 247, expected 73 125
and 146249). *See the ESI† for the expanded region in LC-MS.
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found to hydrolyse extremely rapidly, with a half-life of under a
minute for the C-2 linker, even at the slightly lower pH of 8.0
(Fig. 5). This reveals that bromines serve to further activate the
imide to hydrolysis, through inductive electron-withdrawal.
For comparison, dithiophenolmaleimides were found to
hydrolyse much more slowly (t1/2 = 30–60 min, ESI Fig. S25†),
again highlighting the tuneable reactivity of NGMs.
The significance of this rapid reagent hydrolysis is that the
DBM reagents must conjugate at sub-1 min timescales to
aﬀect eﬃcient conjugation, which is clearly the case in the
antibody conjugations reported herein. Indeed this is con-
firmed by the UV analysis of the conjugation, which reveals the
maximum dithiomaleimide absorbance to be observed
immediately upon taking the first reading (<1 min). It is also
notable that any unreacted DBM reagent post-conjugation will
be rapidly deactivated by hydrolysis. This suggests that there is
unlikely to be any requirement to remove excess reagent post-
conjugation. Indeed we trialled a one-pot conjugation and
hydrolysis in 1 h using reagents 4 and 5, and found that the
outcome by LC-MS was unchanged, eﬃcient conjugation to
generate DAR 4 conjugates.
Maleamic acid stability of C-2 and aryl linkers at low pH
Having previously shown that maleamic acid conjugates are
robustly stable in serum,12d we focused here on further profil-
ing their known susceptibility to cleave at low pH.12a We were
keen to compare the C-2 and aryl linkers described in this work,
in case the nature of the linker aﬀected the rate of cleavage, and
as a result the stability of the conjugates. Thus Alexa Fluor 488®
was attached by a CuAAC reaction onto the pendant alkynes12d
and the conjugates monitored over 24 h by fluorescence
SEC-HPLC (Fig. 6). We chose to compare pH 7.4 which would
approximate the pH in circulation, with pH 5.5 representing
acidic conditions approximating endosomal pH24 (and thus the
most acidic conditions a recycling antibody is likely to experi-
ence, prior to lysosomal degradation). The conjugates with C-2
and aryl linkers showed complete stability at pH 7.4 (even up to
10 days, see ESI Fig. S32†), whilst only the N-aryl conjugate
showed a hint of cleavage at pH 5.5. Overall it can be summar-
ised that maleamic acid antibody conjugates with various
linkers will have robust stability in circulation in vivo.
Fig. 4 Hydrolysis of antibody conjugates monitored by disappearance
of dithiomaleimide absorbance (λmax = 402–406 nm).
Fig. 5 Hydrolysis of the DBM reagents 4 and 5 monitored by the loss of
absorbance at 325 nm.
Fig. 6 Stability of the maleamic acid conjugates with C-2 and aryl
linkers tested at pH 7.4 and 5.5, measured by ﬂuorescence SEC-HPLC
(see the ESI† for traces).
Fig. 7 Deconvoluted LC-MS data on the trastuzumab–NGM conju-
gates: A – using DBM-C2-dansyl (mass observed 73 468 and 146 942,
expected 73 480 and 146 959); C – using DBM-C2-doxorubicin (mass
observed 73 976 and 147 936, expected 73 980 and 147 959).
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Functional DBM conjugation using optimised linkers and
protocols
With improved linkers in hand, and robust stability further
demonstrated, we constructed functionalised antibody conju-
gates using the optimised conditions. The C-2 linker was
selected to avoid the unnecessary incorporation of extra hydro-
phobicity by an aryl ring, whilst dansyl and doxorubicin were
chosen as a model fluorophore and drug respectively. The con-
jugations were carried out using the optimised protocol esta-
blished, 5 min conjugation at pH 8.5 with a further 1 h for
hydrolysis. The LC-MS analysis revealed that the two isomeric
DAR 4 species were again successfully generated (Fig. 7). This
was also consistent with the UV read-out for the doxorubicin
conjugate, which indicated a DAR of 4.1.
Conclusions
Dibromomaleimides with electron-withdrawing C-2 linkers are
demonstrated to oﬀer an optimised bioconjugation platform
for the construction of highly homogeneous and robustly
stable antibody conjugates from native antibodies. These
reagents enable a protocol which takes just over 1 hour for
conjugation and ‘locking’ by hydrolysis, to generate an anti-
body loaded with a DAR of 4. This represents a substantial
improvement in the 72 h protocol previously described for
NGM reagents. By the combined use of these ‘fast-hydrolysing’
linkers and a pH of 8.5, we also show that improved homo-
geneity is inferred on the conjugates. This is due to the rapid
hydrolysis of the dithiomaleimide bridges preventing un-
desired side-reactions, such as C-terminal decarboxylation of
the light chain. It is notable that antibodies themselves are
stable to such short exposure to alkaline conditions. Indeed
they have been reported to only undergo degradation, by
partial asparagine deamidation, under much harsher
conditions (pH 9.2, 45 °C, 48 h), and even then full binding
and structural integrity is retained.25
Whilst other reports in the literature have focused on succi-
nimide hydrolysis as a means to improve the stability of classi-
cal maleimide conjugates from native antibodies, the corres-
ponding ADCs remain a heterogeneous mixture. The DBM
technology combines stabilisation through hydrolysis with a
significant improvement in homogeneity and controlled drug
loading delivered by disulfide bridging, as demonstrated by
LC-MS characterisation. We suggest that these readily available
DBM reagents oﬀer a convenient approach to antibody bio-
conjugation more widely, and can also be applicable to other
peptide, protein and polymer scaﬀolds.
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